Muireann Bolger

Key details

Muireann Bolger is deputy editor of World Intellectual Property Review and Life Sciences Intellectual Property Review in London, where she covers trademarks, brands, as well as wider developments across the intellectual property sector.

She regularly attends and covers major IP conferences around the world, reporting on the latest legal, commercial and policy developments and interviewing leading figures from across the sector. She has also co-authored industry reports with leading IP organisations, including the International Trademark Association (INTA).

She is the editor of the website’s Community & Inclusion channel and the annual Influential Women in IP list, which celebrates the achievements and contributions of leading women across the IP sector.

Originally from Ireland, Muireann has nearly two decades of experience reporting on brand developments, strategy, and wider business issues.

In her current role, she writes and edits news and analysis for an international audience of IP professionals, while also championing inclusion within the profession.

Reset all filters
Article Type
Channels & Sectors
Geography
Company
Refine search
Total results: 415

Articles by Muireann Bolger

Siemens sues ex-VP for stealing heart catheter trade secrets
Pharma
A subsidiary of Siemens AG has accused a former vice president of stealing trade secrets related to heart catheter devices to assist his new employer, NuVera Medical, in developing a rival product.   19 November 2020
Generics sign patent pool pledge to improve access to COVID-19 treatments
Pharma
In response to the surge of COVID-19 infections worldwide, 18 generic drug makers have pledged to join the effort by the Medicines Patent Pool to accelerate global access to effective COVID-19 treatments via a pool for voluntary product licences.   17 November 2020
EC signs contract with Pfizer to access watershed vaccine
Pharma
The European Commission has approved a fourth contract with pharmaceutical companies Pfizer and BioNTech, following their revelation that they had developed a vaccine that could potentially prevent more than 90% of people from becoming infected by COVID-19.   12 November 2020
Americas
Allied BioScience has accused its former CEO of holding the company's IP, including inventions relating to its COVID-19 antiviral disinfectant, to ransom so he can demand an unfair amount of compensation.   12 November 2020
Americas
A coronavirus vaccine unveiled by pharmaceutical companies Pfizer and BioNTech can potentially prevent more than 90% of people from getting COVID-19, it has been announced.   10 November 2020
Pharma
The US Court of Appeals for the Federal Circuit has narrowed the landscape in which patent infringement suits over generic drugs suits can be filed, in a ruling handed down yesterday, November 5.   6 November 2020
Pharma
Biopharmaceutical company, Abbott Laboratories, has successfully obtained a restraining order against its former vice-president of global marketing, whom it has accused of stealing trade secrets relating to COVID-19 products.   5 November 2020
Americas
French drugmaker Sanofi and US biotechnology company Regeneron have secured a victory at the European Patent Office, which has sided in their favour by ruling that a patent belonging to rival Amgen is invalid.   30 October 2020
Americas
Pharmaceutical company Eli Lilly’s subsidiary Dermira has accused generic drugmaker Perrigo of infringing eight patents for Qbrexza, a prescription-only cloth towelette approved to treat hyperhidrosis, a condition that causes excessive underarm sweating.   22 October 2020
Biotech
Talks on a landmark proposal to waive IP rights for vaccines and treatments related to COVID-19 have stalled, following the failure of the World Trade Organisation to conclude an agreement.   20 October 2020

Not finding what you're looking for, please try resetting your applied search and filters,
or try the
full site search.